Blog
FDA Approves First Systemic Treatment for Alopecia Areata
June 2022 – Today, the U.S. Food and Drug Administration approved Olumiant (baricitinib) once a day oral tablets to treat adult patients with severe alopecia areata, a disorder that often appears as patchy baldness and affects more than 300,000 people in the U.S. each year. Today’s action marks the first FDA approval of a systemic treatment (i.e., treats the entire body rather than a specific location) for alopecia areata. The recommended dose is OLUMIANT 2-mg/day, with an increase to 4-mg/day if treatment response is inadequate. For patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4-mg/day. Once an adequate response is achieved on 4-mg/day, the dosage is to be decreased to 2-mg/day.
For more information, visit our Trichology section